{"entity":{"id":"invitae-multi-cancer-panel","kind":"drug","name":"Invitae Multi-Cancer Panel","aka":[],"tldr":"Invitae's broad blood test for inherited cancer risk across many cancer types, now sold under Labcorp.","summary":"Registered in the NIH Genetic Testing Registry as GTR000528909.5 by Invitae (80 genes, entry last updated 7 June 2017), including the solid-tumour predisposition genes and haematological genes such as CEBPA, GATA2 and RUNX1, and DICER1, SMARCB1, PHOX2B, WT1 and GPC3 for childhood tumours. A version with RNA analysis, the Invitae Multi-Cancer + RNA Panel (GTR000597547.2, 2022), lists 63 genes. GTR records it as a test developed by the laboratory; it is not among the FDA-authorised products, unlike Invitae's Common Hereditary Cancers Panel. Labcorp bought select Invitae assets in 2024.","status":"established","asOf":"2026-11-04","links":[{"label":"NIH Genetic Testing Registry GTR000528909.5","url":"https://www.ncbi.nlm.nih.gov/gtr/tests/528909/"},{"label":"NIH Genetic Testing Registry GTR000597547.2","url":"https://www.ncbi.nlm.nih.gov/gtr/tests/597547/"},{"label":"NIH Genetic Testing Registry data file (test_version.gz)","url":"https://ftp.ncbi.nlm.nih.gov/pub/GTR/data/test_version.gz"}],"tags":["test","hereditary"],"related":["invitae-common-hereditary-cancers-panel"],"cancers":[],"sections":[],"technologies":["germline-testing"],"targets":["brca","palb2","tp53","dicer1","smarcb1","runx1","gata2","wt1"],"drugs":[],"companies":["invitae"],"institutions":[],"pathways":[],"terms":["hereditary-cancer-syndromes","beckwith-wiedemann-syndrome","bloom-syndrome","carney-complex"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Invitae Multi-Cancer Panel","modality":"Germline hereditary cancer sequencing panel (laboratory-developed test)","mechanism":"Next-generation sequencing of germline DNA across a broad multi-cancer gene list.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/invitae-multi-cancer-panel/","neighbours":{"drug":[{"id":"invitae-common-hereditary-cancers-panel","kind":"drug","name":"Invitae Common Hereditary Cancers Panel","route":"/drugs/invitae-common-hereditary-cancers-panel/"}],"technology":[{"id":"germline-testing","kind":"technology","name":"Germline (hereditary) testing","route":"/technologies/germline-testing/"}],"target":[{"id":"brca","kind":"target","name":"BRCA1 / BRCA2 (HRD)","route":"/targets/brca/"},{"id":"dicer1","kind":"target","name":"DICER1","route":"/targets/dicer1/"},{"id":"gata2","kind":"target","name":"GATA2","route":"/targets/gata2/"},{"id":"palb2","kind":"target","name":"PALB2","route":"/targets/palb2/"},{"id":"runx1","kind":"target","name":"RUNX1","route":"/targets/runx1/"},{"id":"smarcb1","kind":"target","name":"SMARCB1","route":"/targets/smarcb1/"},{"id":"tp53","kind":"target","name":"TP53","route":"/targets/tp53/"},{"id":"wt1","kind":"target","name":"WT1","route":"/targets/wt1/"}],"company":[{"id":"invitae","kind":"company","name":"Invitae","route":"/companies/invitae/"}],"term":[{"id":"beckwith-wiedemann-syndrome","kind":"term","name":"Beckwith-Wiedemann syndrome","route":"/terms/beckwith-wiedemann-syndrome/"},{"id":"bloom-syndrome","kind":"term","name":"Bloom syndrome","route":"/terms/bloom-syndrome/"},{"id":"carney-complex","kind":"term","name":"Carney complex","route":"/terms/carney-complex/"},{"id":"hereditary-cancer-syndromes","kind":"term","name":"Hereditary cancer syndromes","route":"/terms/hereditary-cancer-syndromes/"}]}}